Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2002 Mar;72(3):300–303. doi: 10.1136/jnnp.72.3.300

Dystonia in multiple system atrophy

S Boesch 1, G Wenning 1, G Ransmayr 1, W Poewe 1
PMCID: PMC1737793  PMID: 11861684

Abstract

Objective: To delineate the frequency and nature of dystonia in multiple system atrophy (MSA).

Methods: a cohort of 24 patients with clinically probable MSA over the past 10 years were prospectively followed up. Motor features were either dominated by parkinsonism (MSA-P subtype, n=18) or cerebellar ataxia (MSA-C, n=6). Classification of dystonic features and their changes with time was based on clinical observation during 6–12 monthly follow up visits. Parkinsonian features and complications of drug therapy were assessed. Most patients (22/24) died during the observation period. Neuropathological examination was confirmatory in all of the five necropsied patients.

Results: At first neurological visit dystonia was present in 11 (46%) patients all of whom had been levodopa naive at this time point. Six patients (25%) exhibited cervical dystonia (antecollis) (MSA-P n=4, MSA-C n=2), five patients (21%) showed unilateral limb dystonia (MSA-P n=4; MSA-C n=1). A definite initial response to levodopa treatment was seen in 15/18 patients with MSA-P, but in none of the six patients with MSA-C. A subgroup of 12 patients with MSA-P developed levodopa induced dyskinesias 2.3 years (range 0.5–4) after initiation of levodopa therapy. Most patients had peak dose craniocervical dystonia; however, some patients experienced limb or generalised dystonia. Isolated peak dose limb chorea occurred in only one patient.

Conclusion: The prospective clinical study suggests that dystonia is common in untreated MSA-P. This finding may reflect younger age at disease onset and putaminal pathology in MSA-P. Levodopa induced dyskinesias were almost exclusively dystonic affecting predominantly craniocervical musculature. Future studies are required to elucidate the underlying pathophysiology of dystonia in MSA.

Full Text

The Full Text of this article is available as a PDF (144.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albanese A., Colosimo C., Bentivoglio A. R., Fenici R., Melillo G., Colosimo C., Tonali P. Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry. 1995 Aug;59(2):144–151. doi: 10.1136/jnnp.59.2.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Askmark H., Eeg-Olofsson K., Johansson A., Nilsson P., Olsson Y., Aquilonius S. Parkinsonism and neck extensor myopathy: a new syndrome or coincidental findings? Arch Neurol. 2001 Feb;58(2):232–237. doi: 10.1001/archneur.58.2.232. [DOI] [PubMed] [Google Scholar]
  3. Berardelli A., Rothwell J. C., Hallett M., Thompson P. D., Manfredi M., Marsden C. D. The pathophysiology of primary dystonia. Brain. 1998 Jul;121(Pt 7):1195–1212. doi: 10.1093/brain/121.7.1195. [DOI] [PubMed] [Google Scholar]
  4. Bhatia K. P., Marsden C. D. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994 Aug;117(Pt 4):859–876. doi: 10.1093/brain/117.4.859. [DOI] [PubMed] [Google Scholar]
  5. Boudin G., Guillard A., Mikol J., Galle P. Dégénérescence striato-nigrique. A propos de l'étude clinique, thérapeutique et anatomique de 2 cas. Rev Neurol (Paris) 1976 Feb;132(2):137–156. [PubMed] [Google Scholar]
  6. Eidelberg D. Functional brain networks in movement disorders. Curr Opin Neurol. 1998 Aug;11(4):319–326. doi: 10.1097/00019052-199808000-00007. [DOI] [PubMed] [Google Scholar]
  7. Fearnley J. M., Lees A. J. Striatonigral degeneration. A clinicopathological study. Brain. 1990 Dec;113(Pt 6):1823–1842. doi: 10.1093/brain/113.6.1823. [DOI] [PubMed] [Google Scholar]
  8. Gilman S., Low P. A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C. J., Kaufmann H., Klockgether T., Lang A. E., Lantos P. L. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999 Feb 1;163(1):94–98. doi: 10.1016/s0022-510x(98)00304-9. [DOI] [PubMed] [Google Scholar]
  9. Goetz C. G., Tanner C. M., Klawans H. L. Bupropion in Parkinson's disease. Neurology. 1984 Aug;34(8):1092–1094. doi: 10.1212/wnl.34.8.1092. [DOI] [PubMed] [Google Scholar]
  10. Gosset A., Pellissier J. F., Delpuech F., Khalil R. Dégénérescence striato-nigrique associée à une atrophie olivo-ponto-cérébelleuse. Etude anatomo-clinique de trois cas. Discussion nosologique. Rev Neurol (Paris) 1983;139(2):125–139. [PubMed] [Google Scholar]
  11. Gouider-Khouja N., Vidailhet M., Bonnet A. M., Pichon J., Agid Y. "Pure" striatonigral degeneration and Parkinson's disease: a comparative clinical study. Mov Disord. 1995 May;10(3):288–294. doi: 10.1002/mds.870100310. [DOI] [PubMed] [Google Scholar]
  12. Hallett M. The neurophysiology of dystonia. Arch Neurol. 1998 May;55(5):601–603. doi: 10.1001/archneur.55.5.601. [DOI] [PubMed] [Google Scholar]
  13. Henry B., Fox S. H., Peggs D., Crossman A. R., Brotchie J. M. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord. 1999 Sep;14(5):744–753. doi: 10.1002/1531-8257(199909)14:5<744::aid-mds1006>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  14. Hughes A. J., Colosimo C., Kleedorfer B., Daniel S. E., Lees A. J. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry. 1992 Nov;55(11):1009–1013. doi: 10.1136/jnnp.55.11.1009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Krauss J. K., Pohle T., Weber S., Ozdoba C., Burgunder J. M. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia. Lancet. 1999 Sep 4;354(9181):837–838. doi: 10.1016/S0140-6736(99)80022-1. [DOI] [PubMed] [Google Scholar]
  16. Krystkowiak P., Martinat P., Defebvre L., Pruvo J. P., Leys D., Destée A. Dystonia after striatopallidal and thalamic stroke: clinicoradiological correlations and pathophysiological mechanisms. J Neurol Neurosurg Psychiatry. 1998 Nov;65(5):703–708. doi: 10.1136/jnnp.65.5.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. LeDoux M. S., Hurst D. C., Lorden J. F. Single-unit activity of cerebellar nuclear cells in the awake genetically dystonic rat. Neuroscience. 1998 Sep;86(2):533–545. doi: 10.1016/s0306-4522(98)00007-4. [DOI] [PubMed] [Google Scholar]
  18. Lehéricy S., Vidailhet M., Dormont D., Piérot L., Chiras J., Mazetti P., Marsault C., Agid Y. Striatopallidal and thalamic dystonia. A magnetic resonance imaging anatomoclinical study. Arch Neurol. 1996 Mar;53(3):241–250. doi: 10.1001/archneur.1996.00550030051022. [DOI] [PubMed] [Google Scholar]
  19. Müller J., Wenning G. K., Jellinger K., McKee A., Poewe W., Litvan I. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology. 2000 Sep 26;55(6):888–891. doi: 10.1212/wnl.55.6.888. [DOI] [PubMed] [Google Scholar]
  20. Odergren T., Stone-Elander S., Ingvar M. Cerebral and cerebellar activation in correlation to the action-induced dystonia in writer's cramp. Mov Disord. 1998 May;13(3):497–508. doi: 10.1002/mds.870130321. [DOI] [PubMed] [Google Scholar]
  21. Perlmutter J. S., Stambuk M. K., Markham J., Black K. J., McGee-Minnich L., Jankovic J., Moerlein S. M. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci. 1997 Jan 15;17(2):843–850. doi: 10.1523/JNEUROSCI.17-02-00843.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Poewe W. H., Lees A. J., Stern G. M. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol. 1988 Jan;23(1):73–78. doi: 10.1002/ana.410230112. [DOI] [PubMed] [Google Scholar]
  23. Poewe W. H., Wenning G. K. The natural history of Parkinson's disease. Ann Neurol. 1998 Sep;44(3 Suppl 1):S1–S9. doi: 10.1002/ana.410440703. [DOI] [PubMed] [Google Scholar]
  24. Poewe W., Lees A. J., Steiger D., Stern G. M. Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology. Adv Neurol. 1987;45:357–360. [PubMed] [Google Scholar]
  25. Quinn N. Multiple system atrophy--the nature of the beast. J Neurol Neurosurg Psychiatry. 1989 Jun;Suppl:78–89. doi: 10.1136/jnnp.52.suppl.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rascol O., Brooks D. J., Korczyn A. D., De Deyn P. P., Clarke C. E., Lang A. E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484–1491. doi: 10.1056/NEJM200005183422004. [DOI] [PubMed] [Google Scholar]
  27. Rivest J., Quinn N., Marsden C. D. Dystonia in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurology. 1990 Oct;40(10):1571–1578. doi: 10.1212/wnl.40.10.1571. [DOI] [PubMed] [Google Scholar]
  28. Schober R., Langston J. W., Forno L. S. Idiopathic orthostatic hypotension. Biochemical and pathologic observations in 2 cases. Eur Neurol. 1975;13(3):177–188. doi: 10.1159/000114674. [DOI] [PubMed] [Google Scholar]
  29. Schrag A., Ben-Shlomo Y., Brown R., Marsden C. D., Quinn N. Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality. Mov Disord. 1998 Nov;13(6):885–894. doi: 10.1002/mds.870130605. [DOI] [PubMed] [Google Scholar]
  30. Schulz J. B., Klockgether T., Petersen D., Jauch M., Müller-Schauenburg W., Spieker S., Voigt K., Dichgans J. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1047–1056. doi: 10.1136/jnnp.57.9.1047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Testa D., Filippini G., Farinotti M., Palazzini E., Caraceni T. Survival in multiple system atrophy: a study of prognostic factors in 59 cases. J Neurol. 1996 May;243(5):401–404. doi: 10.1007/BF00868999. [DOI] [PubMed] [Google Scholar]
  32. Wenning G. K., Ben Shlomo Y., Magalhães M., Daniel S. E., Quinn N. P. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994 Aug;117(Pt 4):835–845. doi: 10.1093/brain/117.4.835. [DOI] [PubMed] [Google Scholar]
  33. Wenning G. K., Ben-Shlomo Y., Hughes A., Daniel S. E., Lees A., Quinn N. P. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):434–440. doi: 10.1136/jnnp.68.4.434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wenning G. K., Tison F., Ben Shlomo Y., Daniel S. E., Quinn N. P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997 Mar;12(2):133–147. doi: 10.1002/mds.870120203. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES